Alkermes plc

NASDAQ:ALKS   3:59:55 PM EDT
24.75
-0.28 (-1.12%)
Products

Alkermes Announces FDA Approval Of Lybalvi For The Treatment Of Schizophrenia And Bipolar I Disorder

Published: 06/01/2021 13:30 GMT
Alkermes plc (ALKS) - Alkermes Announces FDA Approval of Lybalvi™ for the Treatment of Schizophrenia and Bipolar I Disorder.
Alkermes Plc - Commercial Launch Planned for Q4 2021.
Alkermes Plc - New Oral Medication Offers Established Antipsychotic Efficacy of Olanzapine With Less Weight Gain.